Xin Lang Cai Jing·2025-09-29 01:21Core Insights - Baiyunshan Pharmaceutical Group Co., Ltd. has shown a slight increase in stock price by 0.04% on September 26, with a trading volume of 1.52 billion yuan [1] - The company reported a financing buy amount of 20.29 million yuan and a financing repayment of 20.96 million yuan on the same day, resulting in a net financing outflow of 0.67 million yuan [1] - As of September 26, the total financing and securities lending balance for Baiyunshan stands at 1.052 billion yuan, indicating a high level of financing activity [1] Financing Overview - On September 26, Baiyunshan's financing buy was 20.29 million yuan, with a current financing balance of 1.049 billion yuan, representing 2.94% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] Securities Lending Activity - On the same day, Baiyunshan repaid 7,100 shares in securities lending and sold 20,000 shares, amounting to 507,600 yuan based on the closing price [1] - The remaining securities lending volume is 104,500 shares, with a balance of 2.65 million yuan, also above the 90th percentile of the past year [1] Company Profile - Baiyunshan was established on September 1, 1997, and listed on February 6, 2001, with its main business involving the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2] - The company's revenue composition includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2] Financial Performance - For the first half of 2025, Baiyunshan achieved a revenue of 41.835 billion yuan, reflecting a year-on-year growth of 1.93%, while the net profit attributable to shareholders decreased by 1.31% to 2.516 billion yuan [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.906 billion yuan in dividends, with 4.359 billion yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares, and Huatai-PB CSI 300 ETF, which also saw an increase in holdings [3]